drugset / Trial / NCT00548912

Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease

NCT00548912

Phase 4 Withdrawn Dawnmarie DeFazio
NaSingle-groupOpen-labelTreatment

Summary

The hypothesis of this trial is to assess the effect of spironolactone on heart size and mass

Timeline

Start
2007-10
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Spironolactone Small molecule